MANNHEIM, Germany, April 21, 2025 — Affimed N.V. (Nasdaq: AFMD), an immuno-oncology company in the clinical stage focused on empowering patients’ innate ability to combat cancer, announced today the receipt of a notice dated April 15, 2025, from Nasdaq’s Listing Qualifications Department. The notice indicates that the company’s common shares’ bid price has been below the required minimum of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
According to Nasdaq Listing Rule 5810(c)(3)(A), Affimed has an initial 180-day period, until October 13, 2025, to regain compliance. If compliance is not achieved within this timeframe, the company may consider transferring its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market, contingent upon meeting the market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the bid price requirement. Such a transfer would grant an additional 180 days, until April 13, 2025, to regain compliance. However, there is no guarantee that the company will be eligible for this extended compliance period or that Nasdaq will approve the request for continued listing.
The notice does not immediately impact the listing or trading of Affimed’s common shares.
Affimed plans to monitor its common share bid price and explore available options to meet the Minimum Bid Price Rule requirements.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company dedicated to restoring patients’ innate ability to fight cancer by harnessing the untapped potential of the innate immune system. The company’s innate cell engagers (ICE®) facilitate a tumor-targeted approach to identify and eliminate a variety of hematologic and solid tumors. ICE® molecules are created using the company’s proprietary ROCK® platform, which reliably produces customized molecules that utilize the power of innate immune cells to destroy tumor cells. Several ICE® molecules are currently in clinical development, being evaluated as monotherapy or in combination therapies. Headquartered in Mannheim, Germany, Affimed is guided by a team of experienced biotechnology and pharmaceutical leaders with a shared vision of preventing cancer from disrupting patients’ lives. For further details on the company’s team, pipeline, and partners, please visit: .
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements, identifiable by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions. These statements relate to matters including the Company’s compliance with the Minimum Bid Price Rule and the listing or trading of its common shares. Actual outcomes may differ significantly from those projected in these forward-looking statements due to risks, uncertainties, and other factors detailed under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned against placing undue reliance on these forward-looking statements, and the Company undertakes no obligation to revise them, even if new information emerges in the future.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail:
“`
